MedDay SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MedDay SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014290
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MedDay SA (MedDay) is a biotechnology company that develops drugs for brain metabolism to treat diseases of the nervous system. The company provides clinical and pharmaceutical development in the field of rare inborn errors of metabolism. Its pipeline products include molecules such as MD1003, MD1103 and MD1105. MedDay develops products for neurological and psychiatric diseases such as progressive multiple sclerosis, autism spectrum disorders and Alzheimer’s disease. The company utilizes its SPECMET research platforms to discover additional pipeline assets. Its SPECMET metabolomics platform identifies therapeutic targets through cerebrospinal fluid metabolomic analysis. The company operates in Germany and the UK. MedDay is headquartered in Paris, France.

MedDay SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MedDay SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MedDay SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MedDay SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MedDay SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
MedDay SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MedDay SA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
MedDay Acquires Health Division of Profilomic 10
Venture Financing 11
MedDay Raises USD38.7 Million in Series B Financing 11
MedDay Raises US$10 Million In Series A Financing 12
MedDay SA – Key Competitors 13
MedDay SA – Key Employees 14
MedDay SA – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Corporate Communications 16
Apr 27, 2016: MedDay appoints Catherine Moukheibir as Chairman of its Board of Directors 16
Jan 13, 2016: MedDay appoints Philippe Goupit to its Board of Directors 17
Product News 18
10/18/2017: MedDay to Participate in the 7th Joint ECTRIMS – ACTRIMS Meeting in Paris, France 18
09/02/2016: MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal 20
04/21/2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 21
Clinical Trials 23
Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016 23
May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 24
Other Significant Developments 25
Jan 29, 2016: MedDay Notes Acceptance of Manuscript into Journal of Multiple Sclerosis and Related Disorders 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
MedDay SA, Pharmaceuticals & Healthcare, Key Facts 2
MedDay SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MedDay SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MedDay SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MedDay SA, Deals By Therapy Area, 2011 to YTD 2017 8
MedDay SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MedDay Acquires Health Division of Profilomic 10
MedDay Raises USD38.7 Million in Series B Financing 11
MedDay Raises US$10 Million In Series A Financing 12
MedDay SA, Key Competitors 13
MedDay SA, Key Employees 14
MedDay SA, Other Locations 15

★海外企業調査レポート[MedDay SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ViaCyte Inc-製薬・医療分野:企業M&A・提携分析
    Summary ViaCyte Inc (ViaCyte), formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline product portfolio includes VC-01, which is being developed as a therapy for T1D patients who h …
  • SmarTone Telecommunications Holdings Ltd (315):企業の財務・戦略的SWOT分析
    SmarTone Telecommunications Holdings Ltd (315) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Duvel Moortgat NV:企業の戦略的SWOT分析
    Duvel Moortgat NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • V.F. Corporation (VFC):企業の財務・戦略的SWOT分析
    V.F. Corporation (VFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • The Walt Disney Company (DIS):企業の財務・戦略的SWOT分析
    The Walt Disney Company (DIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • The Schwan Food Company:戦略・SWOT・企業財務分析
    The Schwan Food Company - Strategy, SWOT and Corporate Finance Report Summary The Schwan Food Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Syngenta AG:企業の戦略・SWOT・財務分析
    Syngenta AG - Strategy, SWOT and Corporate Finance Report Summary Syngenta AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Aerovironment Inc
    Aerovironment Inc - Strategy, SWOT and Corporate Finance Report Summary Aerovironment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Orsted Salg & Service AS:企業の戦略的SWOT分析
    Orsted Salg & Service AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • ESAB Holdings Ltd:企業の戦略・SWOT・財務情報
    ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Techpool Bio-Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Techpool Bio-Pharma Co Ltd (Techpool Bio-Pharma) is a biopharmaceutical company. The company manufactures urinary protein biopharmaceuticals in critical care conditions. The company’s products include ulinastatin for injection, urinary kallidinogenase for injection, urokinase for injection a …
  • DaVita Inc.:企業の戦略・SWOT・財務情報
    DaVita Inc. - Strategy, SWOT and Corporate Finance Report Summary DaVita Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Kraft Heinz Co:戦略・SWOT・企業財務分析
    The Kraft Heinz Co - Strategy, SWOT and Corporate Finance Report Summary The Kraft Heinz Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • NiSource Inc (NI):企業の財務・戦略的SWOT分析
    NiSource Inc (NI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • LG Electronics Inc (066570):企業の財務・戦略的SWOT分析
    LG Electronics Inc (066570) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Svenska Cellulosa Aktiebolaget:企業のM&A・事業提携・投資動向
    Svenska Cellulosa Aktiebolaget - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Svenska Cellulosa Aktiebolaget Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Medical Facilities Corp (DR):製薬・医療:M&Aディール及び事業提携情報
    Summary Medical Facilities Corp (MFC) is a healthcare service provider that provides inpatient and outpatient surgical procedures. The hospital offers surgical equipment, non-surgical professional services, drugs and supplies, and other support services. Its specialty surgical division performs non- …
  • Medidata Solutions Inc (MDSO)-製薬・医療分野:企業M&A・提携分析
    Summary Medidata Solutions Inc (Medidata) is a provider of cloud based solutions for life sciences sectors. It offers wide range of advanced tools for data & analytics, planning, data capture, study management, monitoring, payments, and platform services. The company offers technology and data analy …
  • Qiagen NV (QIA)-製薬・医療分野:企業M&A・提携分析
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s produc …
  • Real Matters Inc (REAL):企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆